PHOSPHATIDYLINOSITOL 3-KINASE AS A BIOMARKER FOR BREAST CANCER: A REVIEW

Cancer is one of the major causes of death in the world and the second leading cause of death after cardiovascular disease; approximately 70% of deaths from cancer occur in low- and middle- income countries. Breast cancer is the most prevalent cancer and the common cause of cancer mortality worldwide. Modification in various cell signalling pathways promotes cell proliferation, progression and survival. Phosphoinositide 3-kinase (PI3K) pathway is an intracellular signalling pathway that has regulatory roles in cell survival, proliferation, and differentiation. Activation of PI3K pathway contributes to the development of tumour, PI3K is an attractive therapeutic direction in the treatment of cancer. Inhibition of PI3K signalling is effective in the treatment of several types of cancer. In this review, PI3K inhibitors in breast cancer and combination of therapeutics strategies in cancer, importance of PI3K in breast cancer and current clinical studies were addressed.